GENELUX Corp
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
GNLX$1.95-5.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Treasury Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Total | |
| Balance, December 31, 2025 | 38,139,144 | $38 | (433,333) | $(433) | $295,468 | $9 | $(283,538) | $11,544 |
| Stock compensation | - | - | - | - | 1,394 | - | - | 1,394 |
| Unrealized loss on marketable securities | - | - | - | - | - | (14) | - | (14) |
| Fair value of vested restricted stock units | 29,063 | - | - | - | 319 | - | - | 319 |
| Cost of stock option modifications and repricing | - | - | - | - | 68 | - | - | 68 |
| Issuance of common stock for cash | 6,666,667 | 7 | - | - | 18,518 | - | - | 18,525 |
| Issuance of common stock upon exercise of stock options | 5,542 | - | - | - | 13 | - | - | 13 |
| Net loss during the three months ended March 31, 2026 | - | - | - | - | - | - | (8,928) | (8,928) |
| Balance, March 31, 2026 | 44,840,416 | $45 | (433,333) | $(433) | $315,780 | $(5) | $(292,466) | $22,921 |
| Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Additional · Other | ||||||||
| Common Stock · Treasury Stock · Paid-in · Comprehensive · Accumulated | ||||||||
| Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Total | |
| Balance, December 31, 2024 | 34,728,140 | $35 | (433,333) | $(433) | $278,001 | $64 | $(251,393) | 26,274 |
| Unrealized loss on marketable securities | - | - | - | - | - | (35) | - | (35) |
| Stock compensation | - | - | - | - | 1,423 | - | - | 1,423 |
| Issuance of common stock for cash | 3,000,000 | 3 | - | - | 9,550 | - | - | 9,553 |
| Fair value of vested restricted stock units | - | - | - | - | 103 | - | - | 103 |
| Cost of stock option repricing | - | - | - | - | 6 | - | - | 6 |
| Issuance of common stock upon exercise of stock options | 5,000 | - | - | - | 14 | - | - | 14 |
| Net loss during the three months ended March 31, 2025 | - | - | - | - | - | - | (7,492) | (7,492) |
| Balance, March 31, 2025 | 37,733,140 | $38 | (433,333) | $(433) | $289,097 | $29 | $(258,885) | $29,846 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.